The global nonalcoholic steatohepatitis (NASH) treatment market is estimated to reach US$ 19.8 Billion in 2025, expanding at a CAGR of 10.0% from 2017 to 2025, mainly driven by expected approval of Aramchol, Elafibranor, Obeticholic acid, and Simtuzumab, and introduction of several new high-priced products. Moreover, combination therapies are likely to dominate the global market over the forecast period.
Nonalcoholic steatohepatitis (NASH), an extreme form of nonalcholic fatty liver disease (NAFLD), is defined as the presence of hepatic steatosis with inflammation and hepatocyte injury. NAFLD spans a spectrum of clinicopathologic entities from simple hepatic steatosis to nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. Nearly 10% to 20% of the general population affected by NAFLD suffers from NASH. Therefore, the diagnosis methods for NAFLD helps in the prediction of NASH occurrence. The is increasing rapidly in parallel with that of Type 2 diabetes and obesity. NASH is an increasingly common chronic liver disease with worldwide distribution that is closely associated with diabetes and obesity, which have both reached epidemic proportions. It is estimated that there are at least 1.46 billion obese adults worldwide. Approximately 6 million individuals in the USA are estimated to have progressed to NASH and some 600,000 to NASH-related cirrhosis. In the United States, NASH-associated cirrhosis is currently the third most frequent reason for liver transplantation and is predicted to become the leading cause and it is projected to overtake Hepatitis C as the leading cause of liver transplants in the U.S. by 2020.
No medicines have been approved to treat NAFLD and NASH. However, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, improves NASH in patients without diabetes. Targets for therapy are insulin resistance and oxidative stress. Antioxidants and antifibrotic agents, such as vitamin E and pentoxifylline, have not been approved for NASH/NAFLD treatment. Lifestyle changes are encouraged for patients with NASH, including reducing body weight, following a balanced diet, increasing physical activity, and avoiding alcohol. Lifestyle changes are critical in any attempt to reverse the course of NAFLD/NASH, and an evidence-based approved drug therapy for NAFLD/NASH is not available at present. The NASH therapies in clinical pipeline (phase II and III) include Aramchol, ARI 3037MO, BMS-986036, Cenicriviroc (TBR-652), Elafibranor (GF-505), Emricasan (IDN-6556), GR-MD-02, GS-4997, Liraglutide (Victoza/Saxenda), Obeticholic acid (OCA/Ocaliva), Simtuzumab (GS-6624), Tipelukast, and Volixibat (SHP 626).
Visit Nonalcoholic Steatohepatitis Treatment Market by Drug Type (Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines, Vitamin E, Others), Pipeline Analysis (Phase III Drugs – Aramchol (Arachidyl Amido Cholanoic Acid), Elafibranor (GFT505), Emricasan (IDN-6556, PF-03491390), Obeticholic Acid (OCA/Ocaliva), Simtuzumab (GS-6624), Others), and Phase I and II Drugs 2017-2025. The global nonalcoholic steatohepatitis treatment market report provides market size (Revenue US$ Million 2014 to 2025), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021). The global nonalcoholic steatohepatitis treatment market research report is segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. Major players operating in the global nonalcoholic steatohepatitis treatment market and included in this report are AstraZeneca plc, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences Inc., Immuron Ltd., Intercept Pharmaceuticals Inc., Novartis, Pfizer, Sumitomo Dainippon Pharma, Tobira Therapeutics Inc., and Zydus Cadila.
- Drug Type
- Pioglitazone and Type 2 Diabetes Mellitus (T2DM) Medicines
- Vitamin E
- Pipeline Analysis
- Phase III Drugs
- Aramchol (Arachidyl Amido Cholanoic Acid)
- Elafibranor (GFT505)
- Emricasan (IDN-6556, PF-03491390)
- Obeticholic Acid (OCA/Ocaliva)
- Simtuzumab (GS-6624)
- Phase I and II Drugs
- Phase III Drugs
- North America (U.S., Canada)
- Latin America (Brazil, Mexico, Rest of LA)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Rest of the World
- Company Profiles
- AstraZeneca plc
- Conatus Pharmaceuticals
- Galmed Pharmaceuticals
- Genfit Sa
- Gilead Sciences Inc.
- Immuron Ltd.
- Intercept Pharmaceuticals, Inc.
- Sumitomo Dainippon Pharma
- Tobira Therapeutics, Inc.
- Zydus Cadila
To request Table of Contents and Sample Pages of this report visit: